Trial Profile
Single Arm, Phase IIA Clinical Trial Assessing The Safety And Efficacy of Atezolizumab in Combination With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Paclitaxel; Pertuzumab; Trastuzumab
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Jun 2024.
- 10 Mar 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 10 Mar 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.